RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $84 from $81 but keeps a Sector Perform rating on the ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.

This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

Echo IQ executive chair Andrew Grover is generally cheerful and optimistic, but wasn't in the weeks leading up to the US regulator’s approval of its artificial intelligence-based aortic stenosis (AS) ...

Screening rates for hepatitis D virus are not ideal among individuals with hepatitis B virus, who also have a higher all-cause mortality rate.

Exact Sciences (EXAS) is down more than -26% after reporting Q3 ... Laboratories Int (CRL), Corteva Inc (CTVA), CVS Health Corp (CVS), Fair Isaac Corp (FICO), Gilead Sciences Inc (GILD), Host Hotels & ...